Piper Sandler Upgrades Teva Pharmaceutical Indus to Overweight, Raises Price Target to $19
Portfolio Pulse from Benzinga Newsdesk
Piper Sandler analyst David Amsellem upgrades Teva Pharmaceutical Industries (TEVA) from Neutral to Overweight and increases the price target from $12 to $19.
February 12, 2024 | 10:29 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Teva Pharmaceutical Industries upgraded by Piper Sandler from Neutral to Overweight with a price target increase from $12 to $19.
The upgrade from Neutral to Overweight by a reputable analyst, along with a significant increase in the price target, suggests a strong bullish outlook for Teva Pharmaceutical Industries. This is likely to positively influence investor sentiment and could lead to a short-term increase in the stock price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100